Formycon, Santo Holding GmbH deal

In December, Formycon (formerly Nanohale AG) granted investment holding company Santo exclusive, worldwide rights to develop and commercialize an undisclosed biosimilar product. This is the biosimilar company's first licensing deal. Formycon will conduct all further development on behalf of Santo, which will be responsible for development and commercialization costs. Formycon received a singledigit million euro upfront payment and is eligible for milestone payments in the "three-digit million euro range." ...